ZIM
PCRX icon

Zacks Investment Management’s Pacira BioSciences PCRX Stock Holding History

Zacks Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,938
Closed -$262K – 691
2016
Q1 		$262K Buy
+4,938
New +$289K 0.01% 519
2015
Q1 		– Sell
-4,885
Closed -$433K – 686
2014
Q4 		$433K Buy
+4,885
New +$462K 0.01% 444

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Zacks Investment Management's PCRX Position: Q2 2016 in Review

Zacks Investment Management sold out of Pacira BioSciences (PCRX) in Q2 2016, closing a stake of 4,938 shares — an estimated $262K sold.

Zacks Investment Management first reported a position in PCRX in Q4 2014 and held it in 2 quarters. The position peaked at $433K in Q4 2014. 183 funds tracked by Wall St. Rank hold PCRX as of Q2 2016.

  • Zacks Investment Management reported no remaining Pacira BioSciences position as of Q2 2016 after selling out during the quarter.
  • Zacks Investment Management sold 4,938 Pacira BioSciences shares in Q2 2016, an estimated $262K.
  • Zacks Investment Management first reported a position in Pacira BioSciences in Q4 2014 and held it in 2 quarters.
  • Zacks Investment Management's Pacira BioSciences position peaked at $433K in Q4 2014.
  • 183 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2016.

Based on Zacks Investment Management's 13F filing for Q2 2016, filed 15 Aug 2016.